GlassScriptPhysician profile
Richard D Crane
NPI 1013096486
$2,226.22
in general payments reported to CMS, 2019-2025
25 companies · $176 in 2025
The $176 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $442 · 2020: $380 · 2021: $365 · 2022: $231 · 2023: $379 · 2024: $252 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $808.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $807.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $263.39 | 2019-2025 | Repatha, Otezla, Evenity |
| Pfizer INC. | $260.49 | 2020-2024 | |
| Lilly USA, LLC | $233.55 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $225.03 | 2019-2021 | |
| Astellas Pharma US INC | $202.93 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.33 | 2019-2025 | Ofev |
| Glaxosmithkline, LLC. | $155.24 | 2019-2023 | Shingrix |
| Radius Health, INC. | $134.59 | 2020-2025 | Tymlos |
| Novo Nordisk INC | $115.86 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $96.93 | 2019-2022 | |
| Esperion Therapeutics, INC. | $64.00 | 2021-2024 | Nexletol |
| Vanda Pharmaceuticals INC. | $49.46 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $33.79 | 2023 | Austedo Xr |
| Idorsia Pharmaceuticals US INC | $31.15 | 2025 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $27.27 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $24.51 | 2019-2022 | |
| Paratek Pharmaceuticals, INC. | $17.94 | 2022 | |
| Corium, LLC | $16.23 | 2022 | |
| Currax Pharmaceuticals LLC | $16.00 | 2025 | Contrave |
| Novartis Pharmaceuticals Corporation | $15.64 | 2023 | |
| Abbott Laboratories | $13.99 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.19 | 2020 | |
| Daiichi Sankyo INC. | $12.76 | 2020 | |
| Vistapharm, INC. | $11.81 | 2021 | |
| Janssen Pharmaceuticals, INC | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Crane listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.